A 52-Week Study of Bicifadine in Patients With Chronic Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

Summary

This study is to evaluate the long-term efficacy and safety of two dosages of bicifadine SR (600 mg/day and 1200 mg/day) for up to 52 weeks in reducing chronic peripheral neuropathy pain due to diabetes in adult outpatients.

Timeline

Start

2007-10

Primary completion

2008-12

Completion

2008-12

Outcome

Outcome not reported

Stopped: “The 001 trial did not show benefit versus placebo”

Drugs

Indications